Brief: Quantum Biopharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
30/03/2026 14:51
March 30 (Reuters) - Quantum Biopharma Ltd QNTM.CD: QUANTUM BIOPHARMA SIGNS BINDING LETTER OF INTENT WITH ALLUCENT TO CONDUCT PHASE 2 CLINICAL TRIAL IN MULTIPLE SCLEROSIS Source text: ID:nGNXX0CNs Further company coverage: QNTM.CD ((Reuters.Briefs@thomsonreuters.com;))